Prot#D6580C00010: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ej

Project: Research project

Project Details

StatusFinished
Effective start/end date12/16/21 → 12/16/24

Funding

  • AstraZeneca Pharmaceuticals LP (Prot#D6580C00010)